Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants

References

• Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–2064.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045–1052.
   PubMed Web of Science ®Google Scholar
• Coutts J, Fullarton J, Morris C, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020;55(5):1104–1110.
   PubMed Web of Science ®Google Scholar
• Fauroux B, Simões EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173–197.
   PubMed Web of Science ®Google Scholar
• Shi T, Ooi Y, Zaw EM, et al. Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis. 2020;222(Suppl 7):S628–S633.
   PubMedGoogle Scholar
• Berry CE, Billheimer D, Jenkins IC, et al. A distinct low lung function trajectory from childhood to the fourth decade of life. Am J Respir Crit Care Med. 2016;194(5):607–612.
   PubMed Web of Science ®Google Scholar
• Law B, Langley J, Allen U, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806–814.
   PubMed Web of Science ®Google Scholar
• Lanari M, Anderson EJ, Sheridan-Pereira M, et al. Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks’ gestational age in the Northern hemisphere: pooled analysis of seven studies. Epidemiol Infect. 2020;148:e170.
   PubMed Web of Science ®Google Scholar
• Thampi N, Knight BD, Thavorn K, et al. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study. CMAJ Open. 2021;9(4):E948–E956.
   PubMedGoogle Scholar
• Papenburg J, Saleem M, Teselink J, et al. Cost-analysis of withdrawing immunoprophylaxis for respiratory syncytial virus in infants born at 33–35 weeks gestational age in Quebec: a multicenter retrospective study. Pediatr Infect Dis J. 2020;39(8):694–699.
   PubMed Web of Science ®Google Scholar
• Rafferty E, Paulden M, Buchan S, et al. Evaluating the individual healthcare costs and burden of disease associated with RSV across age groups. Pharmacoeconomics. 2022;40(6):633–645.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Dall’Agnola A, Fullarton JR, et al. Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV outcomes study [EROS]). Acta Paediatr. 2018;107(5):854–860.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics. 2005;115(6):1536–1546.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Defoy I, Grubb E. Burden of respiratory syncytial virus hospitalizations in Canada. Can Respir J. 2017;2017:4521302.
   PubMed Web of Science ®Google Scholar
• Robinson JL. Preventing respiratory syncytial virus infections. Paediatr Child Health. 2011;16(8):487–490.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008;28(4):471–480.
   PubMed Web of Science ®Google Scholar
• Smart KA, Paes BA, Lanctôt KL. Changing costs and the impact on RSV prophylaxis. J Med Econ. 2010;13(4):705–708.
   PubMedGoogle Scholar
• Robinson JL, Le Saux N, Canadian Paediatric Society, Infectious Diseases and Immunization Committee, et al. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20(6):321–333.
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization. Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants; [accessed 2023 Mar 15]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/palivizumab-respiratory-syncitial-virus-infection-infants.html#a9
   Google Scholar
• Jalink M, Langley JM. The palivizumab patchwork: variation in guidelines for respiratory syncytial virus prevention across Canadian provinces and territories. Paediatr Child Health. 2021;26(2):e115–e120.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Paes B, Anderson EJ, et al. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol. 2018;53(5):605–612.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. 4th ed.; [cited March 2017; accessed 2022 Aug 31]. Available from: https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. ISPOR-SMDM modeling good research practices task force. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force -1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Paes BA, Li A, et al. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30(8):651–655.
   PubMed Web of Science ®Google Scholar
• Lanctôt K, Saleem M, Kim D. Canadian RSV evaluation study of Synagis® [CARESS] annual report 2016–2017. Toronto (ON): Medical Outcomes and Research in Economics; 2018.
   Google Scholar
• CARESS final data for 32-35 wGA infants. Sunnybrook health sciences centre. Toronto (ON): Sunnybrook; 2022.
   Google Scholar
• Simoes E, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34–42.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799.
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Kusuda S, Mochizuki H, et al. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132(5):811–818.
   PubMed Web of Science ®Google Scholar
• Papenburg J, Defoy I, Massé E, et al. Impact of the withdrawal of palivizumab immunoprophylaxis on the incidence of respiratory syncytial virus (RSV) hospitalizations among infants born at 33 to 35 weeks’ gestational age in the province of Quebec, Canada: the RSV-Quebec study. J Pediatric Infect Dis Soc. 2021;10(3):237–244.
   PubMed Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12(36):1–86. iii,ix–x.
   Web of Science ®Google Scholar
• Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011;15(5):iii–iiv. 1–124.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simões EAF, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–e51.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Anderson EJ, Simões EA, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014;33(6):576–582.
   PubMed Web of Science ®Google Scholar
• Sanchez-Luna M, Burgos-Pol R, Oyagüez I, et al. Cost-utility analysis of palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017;17(1):687.
   PubMedGoogle Scholar
• Carbonell-Estrany X, Pérez-Yarza EG, Sanchez García L, et al. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-the SPRING study. PLoS One. 2015;10(5):e0125422.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95(4):500–505.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161(5):1501–1507.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137–141.
   PubMed Web of Science ®Google Scholar
• Weiner LB, Masaquel AS, Polak MJ, et al. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15(5):997–1018.
   PubMedGoogle Scholar
• Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89(7):673–678.
   PubMed Web of Science ®Google Scholar
• Chiou CF, Weaver MR, Bell MA, et al. Development of the multiattribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care. 2005;17(1):23–30.
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health. Schedule of benefits. Physician services under the health insurance act; [cited 2022 July 01; accessed 2022 Aug 31]. Available from: https://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master.pdf
   Google Scholar
• Canadian Institute for Health Information. Focus on the emergency department. Ottawa (ON): CIHI; 2020 [accessed 2022 Aug 31]. Available from: https://www.cihi.ca/sites/default/files/document/hospital-spending-highlights-2020-en.pdf
   Google Scholar
• Ismaila AS, Sayani AP, Marin M, et al. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med. 2013;13(1):70.
   PubMedGoogle Scholar
• Canada Revenue Agency; [accessed 2022 Jun 20]. Available from: https://www.canada.ca/en/revenue-agency/services/tax/businesses/topics/payroll/benefits-allowances/automobile/automobile-motor-vehicle-allowances/automobile-allowance-rates.html
   Google Scholar
• Statistics Canada. Payroll employment, earnings and hours, and job vacancies; [cited 2021 Oct; accessed 2022 Jun 20]. Available from: https://www150.statcan.gc.ca/n1/daily-quotidien/211223/dq211223b-eng.htm
   Google Scholar
• Statistics Canada. Labour force characteristics, monthly, seasonally adjusted and trend-cycle, last 5 months; [accessed 2022 Jun 20]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1410028701&pickMembers%5B0%5D=1.1&pickMembers%5B1%5D=3.1&pickMembers%5B2%5D=4.8&pickMembers%5B3%5D=5.1&cubeTimeFrame.startMonth=08&cubeTimeFrame.startYear=2021&cubeTimeFrame.endMonth=12&cubeTimeFrame.endYear=2021&referencePeriods=20210801%2C20211201%20
   Google Scholar
• Statistics Canada. Consumer Price Index, monthly, not seasonally adjusted [accessed 2022 Jun 20]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000401
   Google Scholar
• Statistics Canada. Canadian Vital statistics, birth database. Birth statistics for the years 2016–2020. Ottawa (Canada): Statistics Canada.
   Google Scholar
• Narayan O, Bentley A, Mowbray K, et al. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. J Med Econ. 2020;23(12):1640–1652.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group–6. Med Decis Making. 2012;32(5):722–732.
   PubMed Web of Science ®Google Scholar
• Vreman RA, Geenen JW, Knies S, et al. The application and implications of novel deterministic sensitivity analysis methods. Pharmacoeconomics. 2021;39(1):1–17.
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531–537.
   Web of Science ®Google Scholar
• Notario G, Vo P, Gooch K, et al. Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RS V trial by gestational age group. Pediatric Health Med Ther. 2014;5:43–48.
   Google Scholar
• Treasury Board of Canada. Canadian cost-benefit analysis guide – regulatory proposals; [2007; accessed 2022 Jun 20]. Available from: https://www.tbs-sct.gc.ca/rtrap-parfa/analys/analys-eng.pdf
   Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27(9):788–793.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5(4):417–452.
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008;24(11):3223–3237.
   PubMed Web of Science ®Google Scholar
• Griffiths EA, Vadlamudi NK. CADTH’s $50,000 cost-effectiveness threshold: fact or fiction? Value Health. 2016;19(7):A488–A489.
   Web of Science ®Google Scholar
• Ontario Ministry of Health. Respiratory syncytial virus prophylaxis for high-risk infants program reference manual; 2019 [accessed 2022 Aug 31]. Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/funded_drug/pdf/rsv_info.pdf
   Google Scholar
• British Columbia Provincial Health Services Authority. BC RSV immunoprophylaxis program. Administrative manual and decision support tool 2021/2022; [accessed 2022 Aug 31]. Available from: https://www.childhealthbc.ca/sites/default/files/b.c.-rsv-manual-2021-22cc.pdf
   Google Scholar
• Paes B, Fullarton JR, Rodgers-Gray BS, et al. Adoption in Canada of an International Risk Scoring Tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Curr Med Res Opin. 2021;37(7):1149–1153.
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(5 Suppl):S150–S156.
   PubMed Web of Science ®Google Scholar
• Sørensen KG, Øymar K, Dalen I, et al. Asthma, atopy and lung function in young adults after hospitalisation for bronchiolitis in infancy: impact of virus and sex. BMJ Open Resp Res. 2022;9(1):e001095.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Frederix GW, Nibbelke EE, et al. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr. 2018;177(1):133–144.
   PubMed Web of Science ®Google Scholar
• Hansen R, McLaurin K, Sullivan S. Cost-effectiveness of palivizumab prophylaxis by gestational and chronologic age among infants at increased risk of hospitalization for respiratory syncytial virus. AMCP managed care and specialty pharmacy annual meeting 2017. Denver, CO United States. J Manag Care Spec Pharm. 2017;23(3-A SUPPL):S80.
   Google Scholar
• Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425.
   PubMed Web of Science ®Google Scholar
• Hodgson D, Atkins KE, Baguelin M, et al. Estimates for quality of life loss due to respiratory syncytial virus. Influenza Other Respir Viruses. 2020;14(1):19–27.
   PubMed Web of Science ®Google Scholar
• Díez-Gandía E, Gómez-Álvarez C, López-Lacort M, et al. The impact of childhood RSV infection on children’s and parents’ quality of life: a prospective multicenter study in Spain. BMC Infect Dis. 2021;21(1):924.
   PubMed Web of Science ®Google Scholar
• Mitchell I, Paes BA, Lanctôt KL, et al. RSV hospitalization in aboriginal infants in the Canadian registry of Synagis® (CARESS) following prophylaxis (2005–2012). Paediatr Child Health. 2013;18(suppl_A):12A.
   Google Scholar
• Banerji A, Lanctôt KL, Paes BA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian inuit infants. Pediatr Infect Dis J. 2009;28(8):702–706.
   PubMed Web of Science ®Google Scholar
• PATH. RSV vaccine and mAb snapshot; 2023 Jan [accessed 2023 Mar 14]. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/
   Google Scholar
• Bont L, Weil Olivier C, Herting E, et al. The assessment of future RSV immunizations: how to protect all infants? Front Pediatr. 2022;10:981741.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Weinberger DM, Pitzer VE. Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children. NPJ Vaccines. 2022;7(1):127. .
   PubMed Web of Science ®Google Scholar
• Zheng Z. Challenges in maximizing impacts of preventive strategies against respiratory syncytial virus (RSV) disease in young children. Yale J Biol Med. 2022;95(2):293–300. eCollection 2022 Jun.
   PubMed Web of Science ®Google Scholar